JP2024511451A5 - - Google Patents

Info

Publication number
JP2024511451A5
JP2024511451A5 JP2023558498A JP2023558498A JP2024511451A5 JP 2024511451 A5 JP2024511451 A5 JP 2024511451A5 JP 2023558498 A JP2023558498 A JP 2023558498A JP 2023558498 A JP2023558498 A JP 2023558498A JP 2024511451 A5 JP2024511451 A5 JP 2024511451A5
Authority
JP
Japan
Application number
JP2023558498A
Other languages
Japanese (ja)
Other versions
JP2024511451A (ja
JPWO2022200787A5 (https=
Filing date
Publication date
Priority claimed from GBGB2104033.2A external-priority patent/GB202104033D0/en
Application filed filed Critical
Publication of JP2024511451A publication Critical patent/JP2024511451A/ja
Publication of JP2024511451A5 publication Critical patent/JP2024511451A5/ja
Publication of JPWO2022200787A5 publication Critical patent/JPWO2022200787A5/ja
Pending legal-status Critical Current

Links

JP2023558498A 2021-03-23 2022-03-23 選択的アンジオテンシンii受容体リガンド Pending JP2024511451A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2104033.2A GB202104033D0 (en) 2021-03-23 2021-03-23 New compounds
GB2104033.2 2021-03-23
PCT/GB2022/050727 WO2022200787A1 (en) 2021-03-23 2022-03-23 Selective angiotensin ii receptor ligands

Publications (3)

Publication Number Publication Date
JP2024511451A JP2024511451A (ja) 2024-03-13
JP2024511451A5 true JP2024511451A5 (https=) 2025-03-31
JPWO2022200787A5 JPWO2022200787A5 (https=) 2025-03-31

Family

ID=75689748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558498A Pending JP2024511451A (ja) 2021-03-23 2022-03-23 選択的アンジオテンシンii受容体リガンド

Country Status (7)

Country Link
US (1) US20240197685A1 (https=)
EP (1) EP4313977A1 (https=)
JP (1) JP2024511451A (https=)
CN (1) CN117242071A (https=)
CA (1) CA3212188A1 (https=)
GB (1) GB202104033D0 (https=)
WO (1) WO2022200787A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20230600A3 (en) 2022-12-22 2025-09-24 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
KR100938817B1 (ko) * 2001-05-31 2010-01-26 바이코어 파마 아베 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
WO2003064414A1 (en) * 2002-01-29 2003-08-07 Vicore Pharma Ab. Tricyclic compounds useful as angiotensin ii agonists
WO2004046141A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
BR112017012337A2 (pt) 2014-12-12 2018-02-27 Vicore Pharma Ab Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
CN107405406A (zh) 2015-03-02 2017-11-28 维科尔药物公司 用于治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
AR108906A1 (es) * 2016-06-29 2018-10-10 Bristol Myers Squibb Co Heterociclos de biarilmetilo
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds
KR20230004501A (ko) * 2020-03-19 2023-01-06 바이코어 파마 아베 안지오텐신 ⅱ와 관련된 질병, 장애, 또는 병태의 치료 및/또는 예방에 유용한 신규 화합물
GB202013721D0 (en) * 2020-09-01 2020-10-14 Vicore Pharma Ab New compounds
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
JP2024511451A5 (https=)
CL2025003748A1 (es) Plataforma marina flotante de montaje de sistemas de energía renovable.
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13140U (https=)
BY13155U (https=)
BY13144U (https=)
BY13143U (https=)
BY13142U (https=)
BY13141U (https=)
BY23963C1 (https=)
BY13137U (https=)